left-arrow right-arrow pinterest facebook google_plus linkedin

Gastrointestinal Cancer Trials

The following listings are our current trials. If you have questions or want to learn more about the trial, please contact us and provide the Methodist Health System Trial Code listed with the description.


Alliance A021502

Status: Recruiting | Phase III 

Official Title: Testing the Addition of the Antibody Atezolizumab to Usual Chemotherapy after Surgery in Patients with Colon Cancer

Study Purpose: The purpose of this study is to compare any good and bad effects of using the drug atezolizumab along with the usual chemotherapy compared to the usual chemotherapy alone. Learn more


Alliance A021602

Status: Recruiting | Phase III

Official Title: Testing cabozantinib in patients with advanced pancreatic neuroendocrine and carcinoid tumors after progression on everolimus.

Study Purpose: The purpose of this study is to learn if treatment with a drug called cabozantinib to prevent tumor growth is better, the same, or worse than placebo (a pill that contains no active drug). Learn more.


ECOG-ACRIN EA2165

Status: Recruiting | Phase II

Official Title: Testing the Addition of the Drug Nivolumab after Surgery for High Risk Anal Cancer

Study Purpose: To find if adding the study drug, nivolumab (also known as OPDIVO), after standard chemotherapy and radiation will prevent the anal cancer from returning. Learn more. 


Eli Lilly I5B-MC-JGDP

Status: Recruiting | Phase II

Official Title: A Phase II (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine with or without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer

Study Purpose: The purpose is to study the safety of olaratumab in combination with nab-paclitaxel and gemcitabine, or any side effects you might have when you receive the combination treatment. Whether olaratumab in combination with nab-paclitaxel and gemcitabine can help patients with a certain type of pancreatic cancer that has spread to other organs. Learn more


BeiGene BGB-A317-305

Status: Recruiting | Phase II

Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (Bgb-A317) Plus Platinum and Fluoropyrimidine versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Study Purpose: The overall purpose of this study is to compare the effects and safety, of tislelizumab plus chemotherapy to placebo (an inactive substance) plus chemotherapy on you and your Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (GC/GEJ) to find out the most effective treatment. Learn more


HCRN GI14-198

Status: Suspended | Phase II

Official Title: Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab Versus mFOLFIRINOX Plus Placebo in Advanced Pancreatic Cancer Patients.

Study Purpose: To find out the effects, good and/or bad, of adding the study agent ramucirumab to the usual chemotherapy regimen. Learn more


NRG-GI004

Status: Recruiting | Phase III

Official Title: Testing Combination Chemotherapy with or without an Investigational Drug or the Investigational Drug Alone for Metastatic Colon or Rectal Cancer

Study Purpose: To learn if adding the experimental agent atezolizumab (MPDL3280A) to the usual treatment or giving the experimental agent alone is better than the usual treatment alone for metastatic colon or rectal cancer. Learn more


PANOVA-3

Status: Recruiting | Phase III 

Official Title: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma.

Study Purpose: The purpose of this study is to evaluate the efficacy and safety of TTFields together with standard chemotherapy (gemcitabine and nab-paclitaxel) compared to standard chemotherapy (gemcitabine and nab-paclitaxel) without TTFields. Learn more


Pharmatech Lilly J1L-AM-JZGB

Status: Available | Phase III

Official Title: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen

Study Purpose: To determine if an investigational drug, AM0010, in combination with an approved chemotherapy regimen, FOLFOX (oxaliplatin plus 5-fluorouracil (5-FU) plus leucovorin), is safe and effective in the treatment of patients with metastatic pancreatic cancer that has progressed during or following a first-line Gemcitabine containing regimen, compared with FOLFOX alone. Learn more


Pharmatech QBGJ398-301

Status: Available | Phase III

Official Title: A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial

Study Purpose: The PROOF Trial is a clinical research study to determine if the investigational drug, infigratinib, is an effective treatment for cholangiocarcinoma compared with the standard of care, chemotherapy gemcitabine with cisplatin, for patients with a genetic abnormality in the Fibroblast Growth Factor Receptor (FGFR) gene. Learn more


SWOG S1613

Status: Recruiting | Phase II

Official Title: Testing combination antibody treatment with Trastuzumab and Pertuzumab for advanced or metastatic colorectal cancer.  

Study Purpose: The purpose of this study is to compare any good or bad effects of using a combination of antibodies, Trastuzumab and Pertuzumab, to treating with the usual chemotherapy, Cetuximab and Irinotecan. Learn more


SWOG S1815

Status: Recruiting|Phase III

Official Title: Gemcitabine, Cisplatin, And Nab-Paclitaxel Or Gemcitabine And Cisplatin In Newly Diagnosed Advanced Biliary Tract Cancers

Study Purpose: The primary purpose of this study is to compare the effects of adding the drug nab-paclitaxel to the standard of care drugs cisplatin and gemcitabine versus cisplatin and gemcitabine alone. The study wants to find out which treatment approach is better for newly diagnosed advanced biliary tract cancers. Learn more


UNMC 228-17-EP

Status: Recruiting | Phase II

Official Title: Chemotherapy-Related Changes in Neurocognitive Function and Symptoms in Colorectal Cancer Patients: A Pilot Study

Study Purpose: The purpose of this study is to investigate which, when, and where changes in the brain occur between baseline (before the first chemotherapy treatment) and after 12 and 24 weeks of chemotherapy treatment for colorectal cancer. Learn more